5 billion people have access to medicine
2 billion to go

The Access to Medicine Foundation stimulates and guides pharmaceutical companies to do more for the people living in low- and middle-income countries without access to medicine.

Quick access

Our research programmes

Access to
Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Visit this programme

Antimicrobial
Resistance Benchmark

The first report to compare what pharmaceutical companies are doing to bring antimicrobial resistance under control. By highlighting innovative actions, it encourages more companies to seize opportunities for change.

Visit this programme

Access to
Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.

Visit this programme

View all news

Publication - 16 May 2019

Are pharmaceutical companies doing more than ten years ago to improve access to medicine?

The latest report from the Foundation covers 20 of the world’s largest pharmaceutical companies, showing a clear picture of where progress has been made on access to medicine since 2008. It identifies what is driving change toward achieving the SDGs.

View all publications

Event - 04 Dec 2019

RI New York 2019: SDGs and impact investing

On Wednesday 4 December 2019, Bowen Gu, Investor Engagement Manager at the Access to Medicine Foundation will join a panel discussion at RI New York on the SDGs and impact investing.

View upcoming events

What leaders say

The Access to Medicine Index is a very important project. What gets measured, gets done.

Dr. Margaret Chan

Former Director General, World Health Organisation

I’ve been impressed by the Access to Medicine Index. It presents well-balanced stakeholder views on good practices for the pharmaceutical industry and it provides clear standards against which the performance of individual companies can be judged.

Mary Robinson

President, Realizing Rights, Former UN High Commissioner for Human Rights (1997-2002), Former President of Ireland (1990-1997)

When I talk to executives from pharmaceutical companies they tell me that they want to do more for neglected diseases, but they at least need to get credit for it. The Access to Medicine Index does exactly that.